Final results of the initial public offering of Herantis Pharma
Herantis Pharma Plc
Company release 4 June 2014 at 4 p.m.
Not for release or distribution or publication in whole or in part in or into Australia, South Africa, Hong Kong, Japan, Canada or The United States or any other jurisdiction in which the release, distribution or publication would be unlawful.
Herantis Pharma Plc (“Herantis” or “company”) announced by way of a company release published on 12 May 2014 a directed share issue in which the company offers for subscribing a maximum of 1,600,000 new shares. In its release, the company also announced that it will apply for listing of its shares on First North Finland (“First North”), a multilateral trading facility operated by NASDAQ OMX Helsinki Ltd.
The company issued a company release regarding the outcome of the initial public offering on 2 June 2014. Investors subscribed for a total of 1,384,070 shares within the subscription period. The board of directors of Herantis resolved on 30 May 2014 on the approval of the subscriptions made and the number of shares to be issued. The subscriptions were approved on condition that the subscribed shares are paid up in accordance with the share issue terms and conditions no later than on 2 June 2014.
The subscription price was EUR 10.50 per share. In the share issue, in total 1,364,770 shares were subscribed and paid for in accordance with the share issue terms and conditions. Subscriptions which were not paid for in accordance with the share issue terms and conditions were disqualified. Such disqualified subscriptions covered in total 19,300 shares. Thus Herantis raises in total approximately 14.3 million euro in the share issue before the deduction of expenses and fees arising from the share issue, and the number of issued shares in the company will increase to 4,058,214 shares in total.
Herantis has on 12 May 2014 filed an application for admission of the company’s shares to trading on First North with the trading code HRTIS. The shares subscribed for in the share issue are expected to be registered with the Trade Register on or about 6 June 2014, and trading in the company’s shares is expected to commence on or about 11 June 2014.
UB Securities Ltd acted as the Lead Arranger and as the subscription place. The company’s Certified Adviser under the First North rules is UB Capital Ltd. Krogerus Attorneys Ltd acted as legal adviser to the company in connection with the share issue.
Herantis Pharma Plc
Board of directors
Herantis Pharma Plc, Pekka Simula, Managing Director, mobile: +358 40 7300 445
UB Securities Ltd, Herman Segercrantz, Head of Equities, telephone: +358 9 2538 0220, email: email@example.com
Herantis Pharma Plc
Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson’s disease, and secondary lymphedema.
This release is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. Any such offer will be made solely on the basis of a prospectus to be published and registered with the Finnish Financial Supervisory Authority.
This document is not an offer for sale nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area. The securities may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Herantis has not registered and will not register any part of its offering in the United States nor will it offer securities to the public in the United States.
This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
Securities in the company have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan and may not be offered or sold within Australia, Canada or Japan or to, or for the account or benefit of, citizens or residents of Australia, Canada or Japan except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time.
The company does not offer securities to the public in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland (each, a “Relevant Member State”), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may only be offered in Relevant Member States in circumstances not requiring the company to publish a prospectus as provided under the Directive 2003/71/EC.